Molteno implant with mitomycin C: intermediate-term results

J Glaucoma. 1998 Apr;7(2):86-92.


Purpose: The authors examine the intermediate-term effects of adjunctive intraoperative mitomycin C (MMC) in a cohort of patients who received double-plate Molteno implants for complicated glaucomas.

Methods: A consecutive series of 21 patients who received MMC 0.5 mg/ml for 5 minutes as an adjunct to a double-plate Molteno implant was compared by life-table analysis to a historical control group of 18 patients who received either no adjunct or 5-fluorouracil (5-FU) but no MMC.

Results: At three years follow-up, 35% (95% confidence interval (CI), 15-57%) of patients who received MMC avoided failure criteria of intraocular pressure (IOP) less than 6 mm Hg or more than 21 mm Hg, addition of glaucoma medication, reoperation for glaucoma, or tube removal. Seventeen percent (95% CI, 4-37%) of patients in the control group at three years follow-up met similar criteria (p = 0.039). No late complications of tube erosion were seen in the MMC group.

Conclusion: Intraoperative MMC offers an increased likelihood of a two- to three-year period of medication-free IOP control in patients undergoing double-plate Molteno implants, compared to similar patients receiving 5-FU or no adjunctive antimetabolite therapy.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Chemotherapy, Adjuvant
  • Cohort Studies
  • Female
  • Filtering Surgery / instrumentation*
  • Follow-Up Studies
  • Glaucoma / drug therapy
  • Glaucoma / surgery*
  • Humans
  • Intraocular Pressure
  • Male
  • Middle Aged
  • Mitomycin / administration & dosage*
  • Molteno Implants*
  • Ophthalmic Solutions
  • Reoperation
  • Retrospective Studies
  • Treatment Outcome


  • Ophthalmic Solutions
  • Mitomycin